Replies to post #107323 on Biotech Values

[DewDiligence]

Part of the explanation is that BIIB once thought Rituxan would be a big-selling drug in MS.

[DewDiligence]

BIIB cuts workforce by 13% and kills 11 R&D programs:

http://sec.gov/Archives/edgar/data/875045/000095012310099782/b83307e8vk.htm

[genisi]

BG-12 met the primary and secondary endpoints in phase III DEFINE trial

http://www.news-medical.net/news/20110411/Positive-top-line-results-from-Biogen-BG-12-Phase-3-trial-in-RRMS.aspx